Inhibition of prostaglandin F2alpha synthesis and oxytocin receptor by progesterone antagonists in bovine endometrial cells in vitro.
Oxytocin receptor (OTR) expression is suppressed by progesterone (P4) during the luteal phase of the estrous cycle and then it increases at the time of luteolysis, but its regulation is still not completely understood. In vitro studies to determine the mechanism of action are hindered because OTR spontaneously upregulates in vitro and it is impossible to alter expression with P4 or estradiol. During recent studies examining the effect of P4 and an antagonist (mifepristone) on PG secretion, we found that mifepristone attenuated OT-stimulated PG secretion from endometrial epithelial cells. The objective of the present study was to determine, whether this effect of mifepristone was due to changes in prostaglandin synthesis and/or OTR. A time-course showed that mifepristone (5 microM) had no significant effect after 24 h but by 72 h it decreased PGF(2alpha) secretion (P<0.01) and abolished the response of the cells to OT (P<0.01). The presence or absence of P4 did not affect the response to mifepristone. To determine the site of action of mifepristone, cells were cultured for 72 h with or without mifepristone and then COX-1 and COX-2 were measured by Western blotting and OTR was measured by saturation analysis. The results showed that mifepristone did not affect basal or PMA-stimulated expression of either COX-1 or COX-2 but did, however, decrease OTR number (P<0.05). These data demonstrate that OTR and the response to OT can be downregulated in endometrial epithelial cells in vitro via a mechanism involving the P4 receptor.
Goff
Alan K
AK
Centre de Recherche en Reproduction Animale, Faculté de médecine vétérinaire, Université de Montréal, 3200 Rue Sicotte, St-Hyacinthe, Québec J2S 7C6, Canada. goffak@medvet.umontreal.ca
Jamshidi
Ahmad A
AA
Kombé
Aimé
A
D000818:Animals; D002417:Cattle; D002478:Cells, Cultured; D051545:Cyclooxygenase 1 / Q000096:biosynthesis; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D015237:Dinoprost / Q000096:biosynthesis*; D004717:Endometrium / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D030762:Estrous Cycle / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D015735:Mifepristone / Q000494:pharmacology; D011374:Progesterone / Q000037:antagonists & inhibitors*; D018045:Receptors, Oxytocin / Q000037:antagonists & inhibitors*
D018045:Receptors, Oxytocin; D015735:Mifepristone; D011374:Progesterone; D015237:Dinoprost; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2